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Abstract
Intestinal current measurements (ICM) from rectal biopsies are a sensitive means to detect cystic fibrosis
transmembrane conductance regulator (CFTR) function, but have not been optimized for multicenter use. We piloted
multicenter standard operating procedures (SOPs) to detect CFTR activity by ICM and examined key questions for
use in clinical trials. SOPs for ICM using human rectal biopsies were developed across three centers and used to
characterize ion transport from non-CF and CF subjects (two severe CFTR mutations). All data were centrally
evaluated by a blinded interpreter. SOPs were then used across four centers to examine the effect of cold storage on
CFTR currents and compare CFTR currents in biopsies from one subject studied simultaneously either at two sites
(24 hours post-biopsy) or when biopsies were obtained by either forceps or suction. Rectal biopsies from 44 non-CF
and 17 CF subjects were analyzed. Mean differences (µA/cm2; 95% confidence intervals) between CF and non-CF
were forskolin/IBMX=102.6(128.0 to 81.1), carbachol=96.3(118.7 to 73.9), forskolin/IBMX+carbachol=200.9(243.1 to
158.6), and bumetanide=-44.6 (-33.7 to -55.6) (P<0.005, CF vs non-CF for all parameters). Receiver Operating
Characteristic curves indicated that each parameter discriminated CF from non-CF subjects (area under the curve of
0.94-0.98). CFTR dependent currents following 18-24 hours of cold storage for forskolin/IBMX, carbachol, and
forskolin/IBMX+carbachol stimulation (n=17 non-CF subjects) were 44%, 47.5%, and 47.3%, respectively of those in
fresh biopsies. CFTR-dependent currents from biopsies studied after cold storage at two sites simultaneously
demonstrated moderate correlation (n=14 non-CF subjects, Pearson correlation coefficients 0.389, 0.484, and
0.533). Similar CFTR dependent currents were detected from fresh biopsies obtained by either forceps or suction
(within-subject comparisons, n=22 biopsies from three non-CF subjects). Multicenter ICM is a feasible CFTR
outcome measure that discriminates CF from non-CF ion transport, offers unique advantages over other CFTR
bioassays, and warrants further development as a potential CFTR biomarker.
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Introduction
Cystic fibrosis (CF) is the most common lethal genetic
disease in the Caucasian population, with autosomal recessive
inheritance and an incidence of 1:3000 US births [1]. Cystic
fibrosis is caused by mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene, which
encodes the CFTR ATP-binding cassette protein. CFTR is a
chloride and bicarbonate anion channel and regulates the
transport of salt and water across several epithelia [2–7]. The
CFTR gene has >1800 disease-causing mutations, with
deletion of phenylalanine at position 508 found in >85% of CF
patients. F508del-CFTR is rapidly degraded in the 26S
proteosome, with little if any mature protein reaching the
plasma membrane [8–11]. The F508del-CFTR mutation is an
appropriate target for drug development as recent results
indicate that small molecules that modulate F508del-CFTR
maturation (‘correctors’) demonstrate modest bioactivity in
Phase II clinical trials [12].
There are two biomarkers of CFTR function that have been
commonly used to detect the activity of CFTR modulators:
sweat chloride (Cl-) and nasal potential difference (NPD) [13]
[12,14–20]. These bioassays have demonstrated variable
sensitivity to detect CFTR modulator bioactivity, and both
biomarkers have advantages and shortcomings. For example,
while sweat Cl- is feasibly performed in subjects from infancy
through adulthood, it is an indirect measure of CFTR function
that is inextricably linked to sodium absorption through the
epithelial sodium channel (ENaC) [13]. Sweat Cl- values can be
influenced by a number of external factors such as age, salt
intake, aldosterone and other hormone levels, skin integrity,
and additional medical conditions (e.g., ectodermal dysplasia,
thyroid function) that are independent of CFTR activity. NPD is
the only CFTR biomarker commonly used in clinical trials that
fully isolates CFTR activity, thereby providing a high degree of
specificity for functional CFTR at the plasma membrane
[20–22]. However, the test is technically difficult to perform,
may be insensitive to small changes in CFTR function, and is
less feasible in children who cannot cooperate with the test.
Thus, additional CFTR biomarkers that are sensitive and
isolate CFTR activity, are highly discriminatory between CF
and non-CF individuals, can be easily performed in young CF
patients, and monitor CFTR in a target organ with disease
manifestations are needed.
One assay that may address many of these limitations is
Intestinal Current Measurements (ICM) from rectal biopsy
samples [23–30]. This method is attractive since similar
measures of ion transport (e.g., short-circuit current, Isc) with
commercially available equipment are commonly used to
quantify CFTR activity in preclinical model systems (e.g., CF
and non-CF mice and pigs) [31–36]. Furthermore, ex vivo ICM
is a direct assay to isolate and quantify CFTR dependent
currents compared with in vivo measures of nasal potential
difference or Na+ and Cl- ion concentrations (that are the
product of CFTR activity). CFTR is expressed at high levels in
the rectum, the tissue is a target organ of disease that is not
altered by CF manifestations or progression, and the biopsies
are studied ex vivo, all of which provide flexibility in the
reagents that can be used to detect and quantify CFTR activity.
ICM studies of human rectal tissue have been examined for
nearly two decades, predominately in European and more
recently South American CF care and research sites [27,29,37]
[38]. This experience indicates that the assay is safe and well
tolerated, that ICM is sensitive and specific for CFTR function,
and it is highly discriminatory between severe CF (with no
detectable CFTR activity), mild CF (with residual CFTR
activity), and non-CF (normal CFTR function) [25,30] [23,38].
Rectal biopsies can be performed safely in infants and are
routinely used to diagnose conditions in the neonatal period
such as Hirschsprung’s disease. Together, these data provide
strong rationale to examine the feasibility of this assay in a
multicenter format prior to clinical studies of CFTR modulators.
To date there have been no studies of ICM that have used
common SOPs across study centers. This lack of standardized
practices could impede its use as a biomarker in future clinical
trials, where standardized CFTR biomarker procedures (sweat
Cl-, NPD) are important contributors to the successful study of
CFTR modulators [18,20]. It is also unknown whether the
electrophysiologic aspects of the assay (which require
specialized equipment and training) can be centralized (i.e.,
can biopsies performed at a one site be studied by ICM at a
second site) and whether different biopsy methods (e.g., use of
suction or forceps) produce similar ICM data. In the current
study, common SOPs for ICM performance were used across
three CF research sites to generate data regarding ICM
performance in CF patients with severe mutations compared
with non-CF controls. The SOPs were then used to examine
questions relevant to next steps in biomarker development,
including the effects of cold storage on ICM results, the
feasibility of performing ICM on biopsied tissue at a second site
(relative to the site of origin), and ICM characteristics of rectal
biopsies obtained by suction and forceps techniques.
Methods
Ethics statement
This study was approved by the local institutional review
board at each study site, and all clinical investigation was
conducted according to the principles expressed in the
Declaration of Helsinki. All study subjects signed informed
consents for study participation.
Study subjects
Initial studies were completed in non-CF subjects to
demonstrate assay proficiency (five sequential subjects) using
a central data interpreter. Subsequently, CF and non-CF
subjects were enrolled prospectively using the common SOPs
developed by the study team. Non-CF subjects undergoing
scheduled lower endoscopy for clinical purposes (e.g., cancer
screening) were targeted for enrollment, and bowel preparation
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was per the practices of the treating gastroenterologist. All CF
patients underwent the biopsy for research purposes, and
performed a self-administered enema (in each 118 mL
delivered dose, monobasic sodium phosphate monohydrate =
19 gm, and dibasic sodium phosphate heptahydrate = 7 gm)
prior to the procedure. CF patients were offered sedation, and
a simple questionnaire assessing their tolerance of the
procedure was administered following completion.
SOP development
Common equipment, biopsy methods, tissue dissection,
voltage clamp, and reagents were defined based on review of
prior publications, discussions with personnel experienced in
ICM performance, and testing of conditions [23,25,27,29,30].
Personnel from each of the study sites underwent common
onsite training in tissue dissection, mounting, and Ussing
chamber assessment.
Biopsy
Forceps biopsies were performed using the Olympus
endojaw pinless beveled biopsy forceps (FB-230U, Olympus
medical systems, Japan) under direct visualization by a trained
gastroenterologist. Suction biopsies were performed using the
C-Rbi2 rectal biopsy system (Aus systems Pty Ltd, South
Australia, Australia). Biopsies were placed in iced RPMI 1640
buffer, and transported directly to the ICM technician for
dissection and mounting. The time between biopsy and
mounting was typically less than one hour.
Equipment and reagents
Identical voltage clamps and tissue mounts were used at all
study sites (Physiologic Instruments, San Diego, CA), including
VCC MC8 clamps and chambers. Tissues were warmed to
37°C by a circulating pump and continuously gassed with 95%
O2: 5% CO2 in RPMI 1640 media + 25 mM HCO3 unless
indicated otherwise, when Ringers buffer (NaCl 120 mM,
NaHCO3 25 mM, KH2PO4 3.33 mM, K2HPO4 0.83 mM,
CaCl2.2H2O 1.2 mM, MgCl2.6H2O 1.2 mM, and gluconic acid 10
mM) replaced RPMI media. Tissue was dissected under a
dissection microscope, removing the muscularis mucosa
followed by mounting in P2302T, 0.33cm2 sliders. The tissue
was then placed in the Ussing chambers, and voltage clamped
to monitor Isc as previously described [27]. Tissue was treated
with 10 µM indomethacin (mucosal and serosal compartments)
to reduce CFTR dependent Cl- secretion to baseline. Following
stabilization of currents (~30 min) the tissue was treated with
amiloride (100 µM, mucosal compartment) to block Na+
absorption for 15 min. Tissues were then stimulated with 10 µM
forskolin + 100 µM IBMX (mucosal and serosal compartments)
to raise intracellular cAMP and monitored for 20 min. Tissues
were then stimulated with carbachol (100 µM, serosal) to
activate basolateral K+ channels and augment CFTR-
dependent currents. These maneuvers have been shown to
isolate CFTR activity, producing a large CFTR-dependent Cl-
secretory current (serosal to mucosal direction) that is evident
in the presence of functional CFTR at the mucosal plasma
membrane [23,25,27]. In the absence of CFTR, these
maneuvers can produce a small secretory K+ current with a
downward deflection in the Isc. Following current stabilization
(15-20 min), bumetanide (100 µM) was added to the serosal
compartment to block the Na+/K+/2Cl- co-transporter. This
inhibited CFTR-dependent Cl- transport in the presence of
CFTR (downward deflection in Isc), or produced an upward
deflection in the absence of CFTR (inhibition of K+ secretion).
Examples of tracings from non-CF and CF subjects are
included in Figure S1 in File S1. The CFTR blockers CFTRinh-172
(10-50 µM) and GLYH101 (50-100 µM) failed to predictably
inhibit CFTR currents in human rectal biopsy tissue (Figure S2
in File S1), and thus were not routinely used in our studies.
Forskolin, 3-isobutyl-1-methylxanthine (IBMX, a nonspecific
phosphodiesterase inhibitor), carbachol, and bumetanide were
obtained from Sigma-Aldrich, St. Louis, MO, aliquoted into
single use tubes, and stored frozen until the biopsies were
studied. RPMI 1640 media was obtained from Invitrogen,
Carlsbad, CA. CFTRinh172 and GLYH101 were purchased
through the CFFT Compound Distribution Program.
Data collection
Prior to analyses, all data were interpreted by a blinded
reader (site and diagnosis). Each biopsy sample had up to five
Isc parameters calculated, including the change in Isc following
amiloride, forskolin/IBMX, carbachol, forskolin/IBMX +
carbachol, and bumetanide additions. Mean values were
calculated in subjects with multiple biopsies obtained at the
same study site or on the same day.
Statistical analysis
A descriptive analysis was performed with calculation of
means, medians, and standard deviations for continuous data
and percentages for categorical data. Analyses of SOP
effectiveness, including the impact of storage conditions, study
site agreement and extraction method agreement, were
conducted using Isc parameters from biopsies of only non-CF
subjects. The impact of storage condition (cold versus fresh
tissue) on each Isc parameter was examined using the paired t-
test and intraclass correlation coefficient (ICC) analysis [39],
where fresh tissue was considered to be the gold standard. In
addition to the paired t-test and ICC, measurement agreement
between sites with respect to each Isc parameter was assessed
using Bland-Altman analysis [40]; the site of biopsy origin was
treated as the gold standard. Due to the limited number of
subjects providing forceps and suction biopsies, descriptive
statistics for the two methods are shown. For comparisons of
tissue resistance in forceps vs suction biopsies, paired t-tests
were used. Data transformations were used for Isc parameters
to achieve normality assumptions for inferential analyses.
Differences between CF and non-CF subjects with respect to
continuous measures were assessed using the Wilcoxon
Mann-Whitney test. The diagnostic performance of each Isc
parameter at distinguishing CF and non-CF tissues was
examined using Receiver Operator Characteristic (ROC)
curves; results are reported as Area Under the Curve (AUC).
Power analyses were used to determine the capability of ICM
and NPD parameters to detect statistically significant
differences in increasing levels of CFTR function. The
approach was based on a one-sided paired t-test for mean
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differences observed pre- and post-observation with alpha =
0.05, assuming intrasubject correlation of 0.50 between
observation periods. The intersubject SD observed from the
study data was used as the upper bound on calculations.
To assess variance in CFTR responses (intra-site and inter-
site), Analysis of variance (ANOVA) was performed. This
produced the model sum-of-squares (inter-site variation) and
error sum-of-squares (intra-site variation), along with the total
sum-of-squares. This information was then converted to
variances (SD2 / [n -1]).
Agreement analyses for Isc parameters have been back-
transformed to original scale. Model adequacy was verified with
each agreement assessment using residual diagnostics. All
results are reported as mean (95% CI) for continuous data and
N (%) for categorical data unless stated otherwise. Analyses
were performed using R version 2.13 (R Foundation for
Statistical Computing, Vienna, Austria) and SAS version 9.3
(SAS Institute, Cary, NC).
Results
Development of SOPs for ICM performance
The studies supporting SOP development are summarized in
the online Supporting Information, including examples of CF
and non-CF tracings (Figure S1 in File S1), the effects of CFTR
blockers on CFTR currents (Figure S2 in File S1), the impact of
indomethacin on ICM parameters (Figure S3 in File S1),
comparison of buffer conditions (Figure S4 in File S1), and
stimulation with CFTR-activating conditions (Figure S5 in File
S1). Guidelines for SOP development were based on
conversations with experts in the field and published reports
coupled with an overriding goal of a simple, straightforward
assay that utilized common equipment and software
[23,25,27,29,30]. All studies supporting SOP development
were performed in non-CF subjects (n = 5-6 for each
condition). Based upon these results, the reagents and
conditions shown in Figure S1 in File S1 were used for the
ensuing studies.
Prospective multi-center ICM in CF and non-CF
subjects
A total of 45 non-CF and 12 F508del/F508del subjects were
enrolled in this component of the study, and data was available
from 44 non-CF subjects (%) and 11 CF subjects (%). Consent
from one CF and one non-CF subject was withdrawn prior to
biopsy (non-CF subject due to discovery of ulcerative colitis;
CF subject due to painful hemorrhoids). In addition, six CF
subjects were enrolled in a parallel protocol at one site
(genotypes were F508del/F508del for five subjects, E60X/
621+1G-T for the sixth subject). All study conditions were
identical in this parallel study except for the use of Ringers
buffer rather than RPMI 1640 buffer. Based on the similar ICM
results comparing Ringer’s and RPMI buffer (Figure S4 in File
S1), data from these additional CF subjects was included in the
full analysis.
Subject demographics are shown in Table 1. As expected
based on the enrollment populations, the non-CF subjects were
25 years older than the CF subjects, and had a more diverse
racial and ethnic background. Sixty-five percent of CF subjects
were male whereas forty-five percent of non-CF subjects were
male. Enrollment was similar across the three study sites,
ranging between 25%-44% of the total enrollment. A total of
291 biopsies were obtained from all study subjects, with 227
(78%) providing interpretable results based on central
interpretation criteria (stable baseline current and tissue
resistance). A total of six biopsies were inverted (2%) based on
directional responses to agonists and post-analysis un-blinding
to diagnosis (CF or non-CF). Of the 44 non-CF subjects, 37
had bowel preparation with polyethylene glycol (PEG), with a
minority having pre-procedure preparation with magnesium
citrate with or without PEG (n = 4) or not specified (n = 3). A
total of five AEs were reported, including post-procedure
bleeding (n = 4, all self-resolved) and pain from the procedure
(n = 1, self-resolved). All AEs were assessed as probably
related to the procedure by the gastroenterologist. The median
number of biopsies per subject was four (range 2-8), and all
interpretable biopsies were averaged to provide one value per
subject for each of the ICM parameters.
The ICM results for the CF and non-CF subjects across all
study sites are summarized in Table 2. Tissue resistance was
similar for both the CF and non-CF groups (P = NS).
Statistically significant differences in Isc responses between the
CF and non-CF subjects were observed following amiloride (P
= 0.002), forskolin/IBMX (P < 0.001), carbachol (P < 0.001),
forskolin/IBMX + carbachol (P < 0.001), and bumetanide (P <
0.001). The absolute change in amiloride-sensitive current was
greater in the non-CF subjects compared with the CF subjects,
while the changes in all other ICM parameters were as
predicted for the absence of CFTR-function in the CF
compared with the non-CF sample.
The CFTR-dependent responses for non-CF subjects at
each site (forskolin/IBMX, carbachol, forskolin/IBMX +
Table 1. Demographics characteristics by study group.
 non CF CF All
 n = 44 n = 17 n = 61
Age - yrs    
Mean (SD) 56.0 (9.97) 31.0 (8.59) 49.1 (14.8)
Median 54.4 28.2 51.3
Min, Max 26.0, 76.9 21.5, 50.1 21.5, 76.9
Age distribution – no. (%)    
18 - ≤ 24 0 3 (18) 3 (5)
24 - ≤ 36 2 (5) 9 (53) 11 (18)
36 - ≤ 48 4 (9) 4 (24) 8 (13)
> 48 38 (86) 1 (6) 39 (64)
Sex – no. (%)    
Male 20 (45) 11 (65) 31 (51)
Female 24 (55) 6 (35) 30 (49)
Race – no. (%)    
no. with race recorded 44 17 55
Caucasian 35 (80) 16 (94) 45 (82)
African American 8 (18) 1 (6) 9 (16)
Other 1 (2) 0 1 (2)
doi: 10.1371/journal.pone.0073905.t001
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carbachol) and their variances (within and across sites) are
shown in Figure 1A–C and Table 3. Mean and median values
for the three conditions were similar across the three study
sites for the carbachol and forskolin/IBMX + carbachol-
stimulated currents, and one site (S032) in general
demonstrated higher variability for all three stimuli compared
with the other two sites (S076 and S191). Table 3 summarizes
the contribution of inter-site (between) and intra-site (within)
variability to total variability for the same parameters shown in
Figure 1. Greater than 90% of total variance for all three CFTR
measures was due to intra-site variability, and not due to site-
specific differences in assay conduct or results.
ROC curves are shown in Figure 2. All ICM parameters
measured except the response to amiloride produced similar
ROC curves, with AUC values ranging from 94–98%, indicating
that the parameters differentiated CF subjects from non-CF
subjects well. Of the parameters examined, the responses to
forskolin/IBMX, carbachol, and forskolin/IBMX+carbachol had
similar sensitivity. ICM was also capable of detecting partial
CFTR activity. Figure 3 depicts the ICM tracing from one
F508del/F508del subject (male, age 37 years, sweat Cl- = 113
mMol, pancreatic insufficient, FEV1 = 63%) showing features of
functional CFTR, including a clear Cl- upward deflection
following stimulation with forskolin/IBMX (compare with non-CF
Table 2. Summary of changes in Na+ and Cl- ICM currents
(µA/cm2).
 CF Non-CF Difference
Condition n = 17 n = 44 (CF vs non-CF)
Change Amiloride (µA/cm2)
Mean (SD) -10.5 (29.08) -21.4 (27.79) Mean diff = -11.0
Median -1.1 -12.3 95% CI = (6.4, -28.4)
Min, Max -112.5, 7.9 -159, 6 P = 0.002*
Change cAMP (forskolin/IBMX)** (µA/cm2)
Mean (SD) -5.0 (12.67) 99.5 (71.84) Mean diff = 102.6
Median -0.9 92 95% CI = (128.0, 81.1)
Min, Max -35.7, 16.4 6.1, 269.4 P < 0.001*
Change CCh (µA/cm2)
Mean (SD) 5.9 (10.21) 102.2 (69.21) Mean diff = 96.3
Median 3.9 97.26 95% CI = (118.7, 73.9)
Min, Max -12.7, 28.1 0.8, 318.7 P < 0.001*
Change cAMP + CCh (µA/cm2)
Mean (SD) 0.8 (14.66) 201.7 (131.98) Mean diff = 200.9
Median -1.8 193.1 95% CI = (243.1, 158.6)
Min, Max -30.3, 31.9 19.5, 588.1 P < 0.001*
Change Bumetanide (µA/cm2)
Mean (SD) 8.8 (9.7) -35.8 (31.35) Mean diff = -44.6
Median 6.4 -27.4 95% CI = (-33.7, -55.6)
Min, Max -2.6, 30.9 -166.2, 3.3 P < 0.001*
cAMP, forskolin/ IBMX; CCh, carbochol; CI, confidence interval
*. P values were obtained using the Mann-Whitney test
**. Represents the primary clinical endpoint: difference in mean change in current
for cAMP-stimulated tissue between CF and non-CF participants.
ICM data from 16 CF and 41 non-CF subjects were available for analysis.
doi: 10.1371/journal.pone.0073905.t002
result in Figure S1 in File S1). The total change in Isc produced
by forskolin/IBMX+carbachol was 15.8% of the mean wtCFTR
response (non-CF subjects).
Based on the results of these pilot studies, we examined the
power of ICM to detect increasing levels of CFTR function
based on monitoring the ICM response to forskolin/IBMX,
carbachol and forskolin/IBMX + carbachol. We compared this
with the capacity of NPD to detect similar increases in CFTR
activity (change in PD following perfusion with zero Cl- + 10 µM
isoproterenol, a well-defined measure of CFTR activity used to
successfully detect CFTR modulator activity in CF patients
[14,15,18,20,41]. The NPD data was derived from qualification
tracings submitted by 29 NPD study sites that were centrally
interpreted at the Center for CFTR Detection at the University
of Alabama at Birmingham (n = 144 non-CF tracings and 135
CF tracings) [12,18,20,42]. All subjects had a diagnosis of CF
based on standard criteria (sweat Cl- > 60 mMol, organ
manifestations of CF) and received CF care at the submitting
study sites. Genotype information was not included with the
NPD tracings. The results of these comparisons are
summarized in Table 4. All three ICM parameters
Table 3. Camparison of intersite and intrasite variability of









cAMP 384 (8.6) 4069 (91.4) 4453 (100)
CCh 64 (1.6) 3945 (98.4) 4009 (100)
cAMP +
CCh
648 (4.5) 13879 (95.5) 14527 (100)
cAMP, forskolin/ IBMX; CCh, carbochol
doi: 10.1371/journal.pone.0073905.t003
Figure 3.  Partial CFTR function detected in F508del/
F508del CF subject.  Representative tracing from an F508del/
F508del subject with functional F508del CFTR. Adding
forskolin/IBMX to raise cAMP increased the current > 30µA/cm2
which was further augmented by carbachol.
doi: 10.1371/journal.pone.0073905.g003
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Figure 1.  Individual ICM responses across study sites.  Boxplots of CFTR responses in non-CF subjects segregated by site
(site identifiers S032, S076, S191). Whiskers are minimum and maximum values, boxes included data within 25th-75th percentiles,
the horizontal line is the median, and the diamond is the mean. A. Change in Isc following cAMP stimulation (10 µM forskolin/100 µM
IBMX). B. Change in Isc following carbachol (CCh) stimulation (100 µM, basolateral). C. Change in Isc following cAMP + CCh
stimulation (10 µM forskolin, 100 µM IBMX, 100 µM CCh).
doi: 10.1371/journal.pone.0073905.g001
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demonstrated substantially greater power than the NPD to
detect low levels of CFTR function.
CF patient tolerance of the rectal biopsy procedure was
assessed during the study using a simple questionnaire. A total
of eight CF subjects completed this questionnaire post-
procedure. Seven of eight subjects chose to undergo the
procedure without sedation. Subjects were asked to rate the
different aspects of the procedure as ‘not unpleasant’, ‘sort of
unpleasant’, or ‘very unpleasant’, including preparation
(enema), sigmoidoscopy, biopsy, monitoring, and patient
willingness to undergo a rectal biopsy as part of a future study.
The majority of patients rated the enema and sigmoidoscopy
as ‘sort of unpleasant’ (62% and 71%, respectively), while the
majority rated the biopsy and monitoring as ‘not unpleasant’
(71% and 100%, respectively). None of the subjects rated any
of the aspects of the procedure as ‘very unpleasant’, and all
subjects responded that they were willing to undergo rectal
biopsy as part of future CF studies.
Effects of cold tissue storage on ICM parameters
Since ICM performance requires significant onsite training
and equipment, we examined whether the electrophysiologic
aspects of ICM could be centralized. In preparation for these
studies, we examined the effects of different storage conditions
on tissue viability and CFTR activity in non-CF subjects. First,
four separate media conditions for cold storage were compared
(summarized in Figure S6 in File S1). The results indicated that
biopsies stored at 4°C for 18 hours in RPMI 1640 media
retained consistent CFTR dependent responses to agonists.
Subsequently, 17 non-CF subjects underwent forceps-based
biopsy, with half of the biopsies studied immediately and the
other half studied after onsite storage at 4°C (RPMI media +
antibiotics) for 18-24 hours. The results are summarized in
Table 5. The responses to forskolin/IBMX (10/100 µM),
carbachol (100 µM), and forskolin/IBMX + carbachol following
cold storage were reduced relative to responses in fresh tissue
(P = 0.026, 0.046, and 0.039, respectively). The responses
after cold storage were 44%, 47.5%, and 47.3% of the fresh-
Figure 2.  ROC curve analysis.  Note that CF participants are coded as one, and non-CF participants are coded as zero. Average
true-positive rate is the sensitivity of the current to detect CF participants, whereas the average-false positive rate (one-specificity)
marks the cutoff whereby non-CF participants are falsely determined as CF. AUC values varied from 0.946-0.978 for the three
CFTR-specific measurements (forskolin/IBMX (cAMP), carbachol (CCh), cAMP + CCh).
doi: 10.1371/journal.pone.0073905.g002
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tissue responses for the three respective stimulus conditions
(forskolin/IBMX, carbachol, forskolin/IBMX + carbachol).
Variance of ICM CFTR parameters measured in one
subject at two study sites
Based on the observation that cold stored rectal biopsy
tissue retained significant CFTR-dependent currents activity
(Table 5), we examined the intrasubject variance of ICM
parameters, testing biopsies from one non-CF subject studied
at two ICM sites simultaneously. 14 non-CF subjects
underwent forceps-based biopsy, with half of biopsies stored
onsite (4-8°C) in RPMI 1640 media and the other half sent on
ice overnight in RPMI media to a second ICM study site.
Biopsies were then dissected and mounted in Ussing
chambers at the two sites and studied simultaneously (range of
18-24 hours post-biopsy). The ICC coefficients for the three
CFTR-dependent parameters (forskolin/IBMX, carbachol, and
forskolin/IBMX + carbachol stimulated currents) were 0.403,
0.5144, and 0.494, respectively between the two sites. None of
the parameters had differences between sites that reached
statistical significance. Bland-Altman plots are shown in Figure
4A–C, demonstrating that the three ICM parameters had
similar variance between sites independent of the magnitude of
stimulated Isc.
Table 5. Effects of cold storage on ICM parameters (single
site).
Change in Isc µA/cm2 – Least Square Means (Upper C.L., Lower C.L.)
Tissue *cAMP *CCh *cAMP + CCh
Fresh 65.29 (38.23, 102.81) 88.07 (62.34, 120.06) 155.85 (106.34, 218.75)
Stored 28.70 (15.88, 47.04) 41.91 (22.03, 71.16) 73.80 (41.02, 120.58)
cAMP, forskolin/ IBMX; CCh, carbochol
*. P < 0.05 for comparisons between fresh and stored for the different stimuli (n =
17 non-CF subjects)
doi: 10.1371/journal.pone.0073905.t005












Size Number of Subjects
       80% Power 90% Power
NPD:     
Zero Cl/Iso (mV) -22.41 1.18 23.49 (3.94) 10 2.35 0.59 19 26
    20 4.70 1.19 6 8
    30 7.05 1.79 4 5
    40 9.40 2.39 3 4
    50 11.75 2.98 3 3
ICM:     
cAMP (µA/cm2) -99.50 -5.00 94.50 (12.67) 10 9.45 0.75 13 17
    20 18.90 1.49 5 6
    30 28.35 2.24 4 4
    40 37.80 2.98 3 3
    50 47.25 3.73 3 3
CCh (µA/cm2) -102.20 5.90 108.10 (10.21) 10 10.81 1.06 8 10
    20 21.62 2.11 4 4
    30 32.43 3.18 3 3
    40 43.24 4.24 3 3
    50 54.05 5.29 3 3
    60 64.86 6.52 2 3
cAMP + CCh
(µA/cm2)
-201.70 0.80 202.50 (14.66) 10 20.25 1.38 5 7
    20 40.50 2.76 3 4
    30 60.75 4.14 3 3
    40 81.00 5.53 3 3
    50 101.25 6.91 2 3
Iso, isoproterenol; CCh, carbochol
doi: 10.1371/journal.pone.0073905.t004
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Figure 4.  Bland-Altman plots of ICM responses for
biopsies from single subjects studied at two sites
simultaneously after cold storage.  Difference between A.
forskolin/IBMX (cAMP), B. carbachol, or C. forskolin/IBMX
(cAMP + carbachol) responses at site of biopsy origin and test
site. Each dot is the mean ICM response for one subject (both
sites). The X axis is the mean of the response (both sites), and
the Y axis is the difference between the means at the two sites.
The red line is the hypothetical zero difference, and the green
line is the actual mean difference. Blue lines are ± 2 SDs.
doi: 10.1371/journal.pone.0073905.g004
Comparison of CFTR activity in forceps and suction
biopsies
Three non-CF subjects underwent both forceps-based and
suction-based biopsies simultaneously, with subsequent ICM
performance onsite. The Isc responses to forskolin/IBMX,
carbachol, and forskolin/IBMX + carbachol are shown in Figure
S7 in File S1, including individual biopsy results and mean
results for the three subjects (n = 12-14 biopsies per condition).
No significant differences in CFTR dependent currents were
observed based on the nature of biopsy for the three
parameters, but there was a trend towards higher resistance in
forceps biopsies relative to suction biopsies [22.82 ohm·cm2
(±8.85) vs 13.21 ohm·cm2 (±6.55) following subtraction of fluid
resistance, P = 0.056].
Discussion
In this prospective study, we used common SOPs for multi-
center ICM performance and tested their performance in CF
and non-CF subjects. Our data indicated that multiple ICM
parameters performed across three study sites clearly
distinguished between the CF and non-CF condition. Most
notably were changes in Isc produced by forskolin/IBMX,
carbachol, forskolin/IBMX + carbachol, and bumetanide (Table
2). All of these parameters are dependent on CFTR at the
apical plasma membrane. In addition, all of these
electrophysiologic parameters appeared to have similar
sensitivity to discriminate between CF subjects with severe
mutations and non-CF subjects (ROC characteristics, Figure
2). This redundancy provided further assurance of
discrimination by CFTR function, as numerous measures
showed similar behavior by ROC analysis. The one exception
was amiloride-sensitive currents, which were not particularly
discriminatory between CF and non-CF subjects (see Figure
2A). This is not entirely unexpected since ENaC regulation
varies throughout the large intestine and is dependent in part
on local protease activity [43], as well as aldosterone and
volume status. Our results using voltage-clamp conditions were
in good agreement with results reported using open-circuit
conditions, suggesting that the method of monitoring CFTR
was not a major determinant of the measured CFTR dependent
currents [25]. Due to the large difference in ICM responses
between ‘severe’ CF and non-CF subjects with relatively low
variance (Tables 2-4), the power of the assay to detect low
levels of CFTR activity compared favorably with the NPD. Most
of the variance observed in ICM represented differences within
sites and not between sites (Figure 1 and Table 3). Intra-site
variance for CFTR-dependent measures could be due to a
number of contributors, including biologic variability between
subjects, differences in biopsy depth, tissue injury during
dissection, mucosal visualization during the biopsy procedure,
and so on. To ensure optimal assay performance,
standardization of those aspects of ICM that can be
standardized is highly recommended (e.g., equipment,
reagents, software), as are ongoing efforts to minimize the
contributions of site variables (e.g., biopsy techniques, tissue
integrity, dissection). In addition, other stimuli and ion transport
blockers may be considered to reduce variability of CFTR
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dependent responses between subjects (e.g., histamine and
DIDS to isolate CFTR activity).
Previous published work has demonstrated that low levels of
murine F508del CFTR can be monitored by ICM, including ex
vivo treatment with putative F508del corrective agents or
conditions [35,36,44,45]. In addition, Bedwell and colleagues
have shown that transgenic mice carrying the human G542X
mutation in CFTR that are treated with suppressors of
premature termination codons (aminoglycosides, ataluren)
have detectable CFTR function in intestinal tissue studied by
ICM [46–49]. These results in CF animal models support the
notion that monitoring rectal biopsy current is a sensitive assay
to detect restored CFTR function, either in response to ex vivo
treatment of tissue with CFTR modulators (i.e., as a model
system to test modulator activity) or following in vivo treatment
(i.e., as an outcome measure for clinical trials). Future studies
confirming the activity of CFTR modulators in rectal biopsies
from CF patients (treated in vivo or ex vivo) will be necessary
to determine definitively whether ICM is capable of detecting
restored function of human CFTR carrying disease-causing
mutations in human tissue. Rectal biopsies have been used to
monitor F508del CFTR expression in one CFTR modulator trial
(VX-809), using rectal biopsies to assess the maturation of
F508del CFTR by immunoblot [12]. Thirty three of 89 enrolled
subjects voluntarily underwent this optional endpoint in the
VX-809 trial (biopsies prior to and during treatment), supporting
the feasibility of incorporating rectal biopsies into interventional
CF clinical studies. ICM was not included in the analysis of
these biopsies, but evidence suggests that electrophysiologic
measures are more sensitive than biochemical assays to
detect low levels of mature F508del CFTR [29,50].
The studies examining CFTR responses following cold
storage demonstrated that this maneuver reduced currents
substantially (Table 5), but still provided CFTR-dependent
currents that were outside the CF range for fresh tissue (Table
2). Biopsies from single subjects studied after cold storage at
two sites demonstrated moderate correlation between sites and
similar variance over a wide range of detected CFTR activity
(Figure 4A–C), supporting the hypothesis that centralized
performance of the electrophysiologic aspects of ICM may be
potentially feasible. To optimize centralized ICM performance,
minimizing the time between biopsy and electrophysiologic
measurements at the second site are likely critical, including
time between biopsy and transport, and the nature of sample
transportation (e.g., next morning delivery). Finally, the method
of biopsy (suction or forceps) did not clearly influence the
capacity to detect CFTR-dependent currents (Figure S7 in File
S1). Although these studies are limited in number, they do
suggest that sites have flexibility in the nature of rectal biopsy
performance.
Previous studies have helped to define stimuli that reflect
CFTR in the colon, including ENaC blockade with amiloride,
stimulation with cAMP-elevating agents to activate CFTR, and
stimulation of basolateral muscarinic receptors that activate
basolateral K+ channels to hyperpolarize the cell and drive Cl-
exit across the colonocyte apical membrane [23–25,27,51].
Increasing transepithelial Cl- flux via stimulation of basolateral
K+ channels is a unique feature of ICM compared with other
CFTR biomarkers (e.g., sweat Cl- or NPD), providing an
example of how access to the basolateral membrane increases
the flexibility in reagent use to optimize CFTR detection.
The protocol developed in the current study was based on
features previously established by leading laboratories in
intestinal physiology, incorporating aspects from different
practices into the described ICM SOP. Based on
communications with expertise in the field, onsite experience,
and the need to standardize equipment, all sites utilized
common voltage clamps, Ussing chambers, tissue sliders, and
software from a single source. The recirculating chambers (as
opposed to continuous volume-exchange chambers) were
selected based on the availability of standardized equipment
and servicing. Data generated at sites could then be sent
directly to the central reading site for interpretation in a blinded
fashion without concerns of software incompatibilities or
conversion. Our results compare favorably with two recent
studies examining ICM in CF in non-CF subjects. Hirtz and
colleagues demonstrated that ICM was capable of clearly
segregating non-CF subjects from CF patients with either
partial or non-functional CFTR mutations [25]. The cAMP-
stimulated currents reported in non-CF controls and patients
with non-functional CFTR mutations were similar to those
reported here (monitored under open circuit conditions). In a
more recent study reported by Derichs and colleagues,
currents were measured in 309 biopsies from 130 subjects with
pancreatic insufficient CF, pancreatic sufficient CF, an unclear
CF diagnosis, and healthy controls [30]. A cutoff of -34 µA/cm2
was described to discriminate between a CF and non-CF
diagnosis. In agreement with this report, our results defined
95% CI surrounding the CF response to forskolin/IBMX +
carbachol of -30.3 to +31.9 µA/cm2.
Another goal of the project was to develop conditions and a
reagent sequence that would maximize detection of CFTR
activity in a rapid fashion. The results described in Figures S1-
S5 in File S1 support SOPs that include the pretreatment of
samples with indomethacin, that CFTR dependent currents
were similar when using either RPMI or Ringer’s buffer, and
that sequential stimulation with reagents enhanced CFTR
detection. While the durability of modulator drug effects on
mutant CFTR in biopsied rectal tissue are unknown, preclinical
studies with F508del CFTR correctors indicate that the half-life
of F508del CFTR at the airway cell membrane is several hours
[52–54]. Thus, the timeline for ex vivo assessment of CFTR
developed in these studies seems unlikely to limit the capacity
of ICM to detect corrected F508del CFTR at the colonocyte cell
membrane. Unfortunately, neither CFTRinh172 nor GLYH101
were consistently effective blockers of CFTR currents in our
studies (Figure S2 in File S1). The only anion channel that has
been shown to play a major role in the colonocyte apical
membrane to date is CFTR ( [55]). We speculate that mucus
(or other molecules) on the apical surface of the colonic
epithelium may bind the lipophilic blockers or limit access to
CFTR through other molecular interactions. In addition, CFTR
expression in the colon is highest in the base cells of the
colonic crypts, which may limit accessibility of channel blockers
[56]. The Na+/K+/2Cl- cotransporter blocker bumetanide was
thus chosen to inhibit the stimulated currents, although its
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blockade also was incomplete. The direction of Isc inflection
following bumetanide differed between the CF and non-CF
subjects, likely reflecting the nature of the dominant operative
ion transport pathway that was sensitive to bumetanide (CFTR-
dependent Cl- secretion in non-CF subjects, K+ secretion in
CF). This feature, coupled with the direction of inflection
following amiloride (which defines the apical membrane of both
CF and non-CF subjects) helped provide assurance of tissue
mounting and underlying diagnosis. An example of this is
shown in Figure 3, in which the data support the hypothesis
that this subject has detectable F508del CFTR at the colonic
cell membrane. The ICM shows a strong downward deflection
with amiloride (confirming correct orientation), a significant
upward deflection in response to forskolin/IBMX, and a mixed
response to carbachol. Limitations of this study include the
relatively small number of CF subjects enrolled, the lack of CF
patients with pancreatic sufficiency and/or partial function
mutations, and the lack of pediatric subjects. As this study was
performed solely for the purpose of assay development across
three sites and was not designed to provide diagnostic
information to the study population, enrollment of large
numbers of adult or pediatric CF patients was not thought to be
ethical. In addition, insufficient numbers of adult patients with
pancreatic sufficiency or partial function mutations were
available to draw conclusions regarding ICM performance in
this CF subpopulation. In addition, the lack of acute efficacy of
CFTR blockers (CFTRinh172 and GLYH101, Figure S2 in File S1)
and inconsistent increases in sodium absorption in CF biopsies
(Figure 2, Table 2, Figure S1 in File S1) could be limitations to
use of ICM as a CFTR biomarker in modulator trials. Despite
these limitations, our multi-center results demonstrate good
agreement in ICM parameters with single center studies that
have included larger numbers of both adult and pediatric CF
patients and support the hypothesis that multi-center ICM may
be a feasible endpoint for future clinical trials.
In summary, our results indicate that SOPs for ICM
performance can be developed across three centers, that multi-
center ICM can discriminate between CF patients with severe
CFTR mutations and non-CF subjects, and that ICM
(performed with common SOPs) can detect partial CFTR
function in CF patients. The power of multi-center ICM to detect
low levels of CFTR activity compares favorably with that of
multi-center NPD. CFTR activity was detectable several hours
post-biopsy with moderate correlation between study sites,
suggesting that the electrophysiologic aspects of ICM can
potentially be centralized in the future. The assay expands
upon available CFTR biomarkers by isolating CFTR currents,
providing flexibility in reagents, and offering numerous CFTR-
specific features that discriminate between CF and non-CF
subjects. Together, these data demonstrate that ICM is a
feasible biomarker for CFTR and that further development is
warranted for application to clinical trials.
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